JP

John Pribis

Co-Founder, Head of Business Strategy, Solu Tx; Entrepreneur, Company Creator

Brookline, Massachusetts

Investor
VC

Invests in

Stages:

Series A
Seed

  • Min Investment:

    $100,000.00

  • Max Investment:

    $5,000,000.00

  • Target Investment:

    $1,500,000.00

Skills

Written Communication
Incubation
Venture Capital
Bioinformatics
Research
Data Analysis
Drug Discovery
Genetic Engineering
Molecular Biology
Molecular Cloning
Proteomics
PCR
Cell Culture
Biochemistry
Cell Biology
Western Blotting
Genetics
Science
Life Sciences
Microscopy

Education

Lists including John

AT
AS
AT
AH

All Series A Investors

14752 people

AM
AT
AS
AR

All Seed Investors

19695 people

Work Experience

ST
Solu Therapeutics

2022

  • Co-founder, Head of Business Strategy

    2024

  • Co-founder and Head of BD, Strategy, and Operations

    2023 - 2024

  • Founding VP of Strategy and Operations

    2022 - 2023

LF
Longwood Fund

2021 - 2023

  • Senior Associate

    2021 - 2023

DB
DEM Biopharma, Inc.

2021 - 2022

  • Co-founder, VP Strategy & Operations

    2021 - 2022

FL77, Inc

2020 - 2021

  • Co-founder, FL77, Inc (Apriori Bio)

    2020 - 2021

FP
Flagship Pioneering

2019 - 2021

  • Associate

    2019 - 2021

  • Flagship Venture Fellow

    2019 - 2019

BC
Baylor College of Medicine

2013 - 2019

  • Graduate Student

    2013 - 2019

    Mechanisms of Antibiotic Resistance and Bacterial Evolvability

Uo
University of Pittsburgh

2008 - 2013

  • Director of Tri-Institutional Drug Discovery Program & Research Fellow

    2008 - 2013

    Team leader of a tri-institutional drug discovery program that led to the discovery of several drugs to treat sterile inflammation. Inflammation, traumatic injury, and susceptibility to infection after injury.